The Cytokines IL-1β and IL-1 Receptor Antagonist, IL-2 and IL-2 Soluble Receptor-a, IL-6 and IL-6 Soluble Receptor, TNF-a and TNF Soluble Receptor I, and IL10 in Drained and Systemic Blood after Major Orthopaedic Surgery

References

• Andrejko KM, Deutschman CS. Acute-phase gene expression correlates with intrahepatic tumour necrosis factor-cc abundance but not with plasma tumour necrosis factor concentrations during sepsis/systemic inflamma-tory response syndrome in the rat. Crit Care Med 1996; 24: 1947–1952.
   Google Scholar
• Arnestad JP, Bengtsson A, Bengtson JP, et al. Formation of cytokines by retransfusion of shed whole blood. Br J Anaesth 1994; 72: 422–425.
   Google Scholar
• Arnstad JP, Bengtsson A, Bengtson JP, et al. Release of cytokines, polymorphnuclear elastase and terminal C5b-9 complement complex by infusion of wound drainage blood. Acta Orthop Scand 1995; 66(4): 334–338.
   Google Scholar
• Blevins FT, Shaw B, Valeri CR, et al. Reinfusion of shed blood after orthopaedic procedures in children and adolescents. J Bone Joint Surg 1993; 75A: 363–371.
   Google Scholar
• Cavaillon J-M, Fitting C, Haeffner-Cavillion N. Re-combinant C5a enhances interleukinl and tumour necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol 1990; 20: 253–257.
   Google Scholar
• Cruickshank AM, Fraser WD, Burns HJG, et al. Response of serum Interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci 1990; 79: 161–165.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Biologic basis for Interleukin-1 in disease. Blood 1996; 87: 2095–2147.
   PubMed Web of Science ®Google Scholar
• Faris PM, Ritter MA, Keating EM, Valeri CR. Un-washed, filtered, shed blood collected after knee and hip arthroplasties. J Bone Joint Surg 1991; 73A: 1169–1178.
   Google Scholar
• Fong Y, Lowry SF. Tumour necrosis factor in the pathophysiology of infection and sepsis. Clin Immunol Immunopathol 1990; 55: 157–170.
   PubMedGoogle Scholar
• Heinrich PC, Graeve L, Rose-John S, et al. Membrane bound and soluble interleukin-6 receptor: studies on regulation of expression and signal transduction. Ann NY Acad Sci 1995; 762: 222–237.
   Google Scholar
• Hempel L, Körholz D, Honig H, et al. Interleukin-10 directly inhibits the interleukin production in T-cells. Scand J Immunol 1995; 41: 462–466.
   PubMedGoogle Scholar
• Hirano T, Matsuda T, Nakajima K. Signal transduction through gp 130 that is shared among the receptors for the interleukin 6 related cytokine subfamily. Stem Cells 1994; 12: 262–277.
   Google Scholar
• Krohn CD, Reikeris 0, Mollnes TE, Aasen AO. Complement activation and release of interleukin-6 and tumour necrosis factor-cc in drained and systemic blood after major orthopaedic surgery. Eur J Surg 1998; 164: 103–108.
   Google Scholar
• Mackiewicz A, Rose-John S, Schooltink H, et al. Soluble interleukin-6-receptor modulates interleukin-6-dependent n-glycosylation of alphal-protease inhibitor secreted by HepG2cells. Fed Eur Biochem Soc 1992; 306: 257–261.
   Google Scholar
• Malefyt R de W, Abrams J, Bennet B, et al. Inter-leukin10 (IL10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209–1220.
   Google Scholar
• Minami Y, Taniguchi T. IL-2 signalling: recruitment and activation of multiple protein tyrosine kinases by components of the IL-2 receptor. Curr Opin Cell Biol 1995; 7: 156–162.
   PubMedGoogle Scholar
• Okusawa S, Dinarello CA, Yancey KB, et al. C5a induction of human interleukin 1. J Immunol 1987; 8: 2635–2640.
   Google Scholar
• Ohmori Y, Hamilton T. Regulation of macrophage gene expression by T-cell derived lymphokines. Pharmacol Ther 1994; 63: 235–264.
   PubMed Web of Science ®Google Scholar
• Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12: 227–257.
   PubMed Web of Science ®Google Scholar
• Rose-John S, Ehlers M, Grötzinger J, Mtillberg J. The soluble Interleukin-6 receptor. Ann NY Acad Sci 1995; 762: 207–221.
   PubMed Web of Science ®Google Scholar
• Saatvedt K, Lindberg H, Geiran OR, et al. Complement activation and release of tumour necrosis factor alpha, interleukin-2, interleukin-6 and soluble tumour necrosis factor and interleukin-2 receptors during and after cardiopulmonary bypass in children. Scand J Clin Lab Invest 1995; 55: 79–86.
   PubMed Web of Science ®Google Scholar
• Schulze S, Drenck NE, Hjortso E, Kehlet H. Influence of combined neural blockade H1- and H2-receptor and serotonin2-receptor blockade, indomethacin and tran-examic acid on leukocyte, temperature and acute-phase protein response to surgery. Acta Chir Scand 1988; 154: 329–333.
   Google Scholar
• Sch(ibitz B, De Kloet ER, Halsboer F. Gene expression and function of interleukin 1, interleukin 6 and tumour necrosis factor in the brain. Prog Neurobiol 1994; 44: 397–432.
   Google Scholar
• Stewart RJ, Marsden PA. Biologic control of the tumour necrosis factor and interleukin-1 signalling cascade. Am J Kidney Dis 1995; 25: 954–966.
   PubMed Web of Science ®Google Scholar
• Tang G-J, Cheng-Deng K, Tzu-Chen Y, et al. Pen-operative plasma concentrations of tumour necrosis factor-cc and interleukin-6 in infected patients. Crit Care Med 1996; 24: 423–428.
   PubMedGoogle Scholar
• Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; i: 355–357.
   Google Scholar
• Waldmann T. The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 1993; 14: 264–270.
   PubMedGoogle Scholar